Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic changes in breast cancer--consequences for therapy?

K Dhingra1, W N Hittelman, G N Hortobagyi

  • 1Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Gene
|June 14, 1995
PubMed
Summary

Understanding genetic changes in breast tumors is key for better prevention and treatment. Targeting specific genetic lesions offers a promising future for personalized breast cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Letter to the Editor, "3D-Printed Polycaprolactone Reinforced Hydrogel as an Artificial TMJ Disc".

Journal of dental research·2021

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Genetic alterations are fundamental to breast tumor development and progression.
  • Specific genetic changes influence tumor behavior, including proliferation and invasion.
  • Other genetic alterations lead to instability, promoting further mutations relevant to tumorigenesis.

Purpose of the Study:

  • To highlight the critical role of understanding genetic changes in breast tumors.
  • To discuss the implications of these genetic changes for prognosis and therapy.
  • To envision future personalized treatment strategies based on tumor genetics.

Main Methods:

  • Review and synthesis of current knowledge on genetic alterations in breast tumors.
  • Correlation of genetic changes with clinical outcomes and prognosis.

Related Experiment Videos

  • Analysis of early clinical trials investigating targeted genetic therapies.

    • Main Results:

    • Numerous genetic changes identified in breast tumors, impacting transformation and genetic instability.
    • Correlation between specific genetic alterations and adverse prognosis.
    • Proof of concept established for targeting specific genetic lesions therapeutically.

    Conclusions:

    • Knowledge of breast tumor genetics is essential for improved understanding, prevention, and treatment.
    • Genetic profiling of tumors will likely guide future personalized therapeutic approaches.
    • A shift towards targeted therapies based on individual tumor genetics is anticipated.